I’m Julien Willard, a physician and economist who helps biotech and pharma leaders with strategy, investor relations, and deals.

Now

  • Fractional Chief Operating and Financial Officer ThreeO Therapeutics
  • Senior Advisor, Royalty Investments BioPalace
  • Managing Member Arcstone Strategy Group
Julien Willard, in a blue blazer and open-collared white shirt, smiling

Good science fails without good strategy. I work to close that gap.

Black-and-white studio portrait of Julien Willard
Julien Willard, MD, MPH

For nearly 15 years, I have advised senior leadership in life sciences – at the World Bank, Oxfam, IBM Life Sciences, and Accenture Strategy. In every role, the work has been the same: helping biopharma executives make consequential decisions on capital allocation, M&A, restructuring, technology strategy, and market access.

My background is an unusual mix. I trained as a physician in Moscow, then in health economics at the London School of Hygiene and Tropical Medicine as a Melinda Gates Scholar, and I have advised at the level of national economic policy. Most of my work now is closer to the operating problems companies actually face: raising and allocating capital, structuring transactions and partnerships across borders, and building the operating discipline that turns funded strategy into working companies. I live in San Diego.

Read the full biography

By the numbers

  • $35B+

    In biopharma transactions advised, on the buy side and the sell side

  • $1B

    Restructuring led end to end: P&L, workforce, and operating model

  • $125M+

    In capital raised for healthcare and life sciences

  • $130M

    HIV vaccine program managed end to end across research, funding, and delivery partners

Select deals

Transaction and post-merger integration advisory.

  • Acquisition
  • Separation and IPO
  • Acquisition

Where I work now, and where I have worked in biopharma

  1. Economic intelligence, market access, international finance

    • Oxfam GB 2007-15
    • World Bank 2015-18
    • The White House 2016-17
  2. Corporate strategy and digital strategy

    • Accenture Strategy 2019-22
    • IBM Consulting 2022-25
  3. Corporate development, M&A, licensing

    • Arcstone Strategy Group since 2018
    • BioPalace since 2025
    • ThreeO Therapeutics since 2026

I help founders work through six common requests

Let me know if this resonates with you.

On stage, on air and in print

I speak and write on AI in drug development, biotech dealmaking, and the economics of pharma.

The biotech CEO job after the Series A

With David Crean, PhD, MBA, managing partner at Cardiff Advisory

In this Spotify episode, we cover the skills that a CEO needs to learn post-Series A.

Off-Label54 minutes

Open in Spotify

What I talk about

  • The Molecule Economy in the AI eraMarket-aware and technology-native corporate strategy
  • Biopharma deal autopsiesLearning from M&A and licensing, including China and broader APAC deal flow.
  • Alternative sources of capital for biotechsDebt, royalty financing and private capital, and capital allocation against value creation.
  • Human intelligence for CEOsPeople, strategy and intelligence skills CEOs need.

References

Julien helped to build our R&D roadmap and market analysis across teams on two continents, ready to be presented to our board. You do not need to manage him.
Kate Broderick, PhDChief Science Officer, Artis
He possesses two critical traits: non-intuitive thinking and skill in high-pressure negotiations. He is a very confident and ruthless operator.
Ellen BienCFO / Ministry of Defense, The Netherlands
Dr. Willard is uncompromising in his strategic focus. He is rare, a physician who understands both the science and the boardroom.
Lidia FonsecaEVP / Pfizer
Julien is a perfectionist. He is no yes-man; expect pushback, grounded in data and research.
Carissa Rollinsformer CIO / Illumina
One of the few advisors I have worked with who connects global supply chain, corporate strategy, and digital into a single point of view. He earns the room.
Mike McDermottEVP, Chief Global Supply and Quality Officer / Pfizer
He is able to range in his thinking from high-level systems analysis and business planning to very specific implementation challenges.
Denis McDonoughformer White House Chief of Staff

If you need a strategist and operator, I would welcome a conversation.

I work with biopharma leadership ready to win at all costs: on transactions, on growth, on the hard operational decisions that separate companies that scale from those that stall.